Shelia Violette

Dr. Violette was previously Vice President of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. From 2008 to 2012, Dr. Violette was Vice President of Research at Stromedix and led all research activities supporting the development of the αvβ6 antibody, STX-100. Dr. Violette has more than 20 years of industry experience advancing programs from early research to clinical development. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 90 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She is currently Chief Scientific Officer, Admirx, Cambridge, MA. Dr. Violette received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training in the Department of Biology at Yale University.